Australian Respiratory and Sleep Medicine Institute Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3

Organization Overview

First Clinical Trial
2015
NCT02335164
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

ARASMI | Australian Respiratory and Sleep Medicine Institute | Australian Respiratory and Sleep Medicine Institute Ltd

Active Ingredients

Drugs in Phase 3 Trials (3)

advax (2 trials)

covax-19 (1 trial)

mrna-1273 (Spikevax) (1 trial)

Drugs in Phase 2 Trials (1)

hepadvax (1 trial)

Drugs in Phase 1 Trials (2)

Autologous tumor vaccine (1 trial)

recombinant influenza hemagglutinin (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Hepatitis (Phase 2)

Hepatitis A (Phase 2)

Hepatitis B (Phase 2)

Hepatitis B, Chronic (Phase 2)

Hepatitis, Chronic (Phase 2)

Herpesviridae Infections (Phase 2)

Influenza, Human (Phase 1)

Influenza in Birds (Phase 1)

Virus Diseases (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 7
  • # of Trial APIs: 6